Methylation status of RASSF1A and clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer.
10.3969/j.issn.1672-7347.2011.07.008
- Author:
Guiyuan XIE
1
;
Chunhong HU
;
Ming HUANG
Author Information
1. School of Public Health, Central South University, Changsha 410078, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Carcinoma;
drug therapy;
genetics;
Cisplatin;
administration & dosage;
DNA Methylation;
Female;
Humans;
Middle Aged;
Neoadjuvant Therapy;
methods;
Ovarian Neoplasms;
drug therapy;
genetics;
Paclitaxel;
administration & dosage;
Promoter Regions, Genetic;
Tumor Suppressor Proteins;
genetics;
Young Adult
- From:
Journal of Central South University(Medical Sciences)
2011;36(7):631-633
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the relation between methylation status of RAS association domain family 1A (RASSF1A) in patients with advanced epithelial ovarian cancer and the clinical efficacy of cisplatin based neoadjuvant therapy.
METHODS:Forty patients with advanced epithelial ovarian cancer were selected and the methylation status of RASSF1A was evaluated by methylation specific PCR (MSP). The clinical efficacy was compared between patients with different methylation statuses of RASSF1A.
RESULTS:The response rate of 15 patients with methylation status in the promoter region was 26.6% and that of 25 patients without methylation status was 48.0%, with significant difference (P<0.05).
CONCLUSION:The methylation status of RASSF1A can influence the clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer.
